Lauren Dembeck, PhD

Contributing Writer https://www.hematologyadvisor.com

Lauren Dembeck is a freelance science and medical writer and a contributing author for the Haymarket Medical Network. She holds a BS in biology and a BA in foreign languages from West Virginia University and a PhD in genetics from North Carolina State University. Prior to freelance writing, Lauren was a postdoctoral researcher at the Okinawa Institute of Science and Technology in Japan, where she studied developmental neurobiology. You can find more of her writing at https://laurendembeck.com/.

All articles by Lauren Dembeck, PhD

Monitoring patient status in the infusion room.

Leukemia

Sorafenib Maintenance Therapy After Allo-HSCT Improves Outcomes in FLT3-ITD–Positive AML

Lauren Dembeck, PhD

July 29, 2020

Among patients with FLT3-internal tandem repeats, sorafenib maintenance therapy reduces the risk of relapse and death after allo-HSCT.

General Hematology

Fertility Preservation Counseling Before Chemotherapy May Be Infrequent

Lauren Dembeck, PhD

July 29, 2020

Clinicians are more likely to counsel younger and female patients on reproductive risks before initiating chemotherapy, despite available ASCO guidelines.

african american woman vaping and exhaling cloud of smoke

Anemia

Does Inhaled Cannabis Reduce Pain in Adults With Sickle Cell Disease?

Lauren Dembeck, PhD

July 28, 2020

Investigators aimed to determine whether vaporized cannabis would reduce symptoms of chronic pain in adult patients with sickle cell disease.

Red blood cells macro over red eritrosit background.

Bleeding Disorders

The Utility of Disease Registries to Assess Inhibitor Development in Hemophilia A

Lauren Dembeck, PhD

July 17, 2020

Researchers assessed whether hemophilia A disease registry could be used instead of clinical studies to determine orphan drug safety in pediatric patients.

Thrombotic Disorders

Comparison of Early and Late Transplant-Associated Thrombotic Microangiopathy

Lauren Dembeck, PhD

July 16, 2020

Although etiologies and traits of early and late thrombotic microangiopathy may vary, outcomes for both patient populations are similarly unfavorable.

Leukemia

Risk-Adapted Therapy Prevents Fungal Infections in Childhood Leukemia

Lauren Dembeck, PhD

July 16, 2020

Risk-adapted therapy effectively prevents fungal infections and reduces neurotoxicity in children with leukemia.

Anemia

Comparison of Fixed-Dose, Dose-Escalated Hydroxyurea in Pediatric Sickle Cell Anemia

Lauren Dembeck, PhD

July 14, 2020

Investigators compared fixed dose and dose escalation administration of hydroxyurea in pediatric patients with sickle cell anemia.

Anemia

Thrombosis and Iron Deficient Anemia: Determining Trends in Thrombotic Complications

Lauren Dembeck, PhD

July 14, 2020

Although the association between thrombocytosis in iron deficiency anemia is understood, researchers studied the risk for thrombotic complications.

Leukemia

Benefit From CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell ALL

Lauren Dembeck, PhD

June 29, 2020

Patients with B-cell ALL who are treated with CAR T-cell therapy and allo-HSCT may have better outcomes than those treated only with CAR T-cell therapy.

Over half of evaluable patients who received an infusion of tisagenlecleucel achieved response.

Lymphoma

Addition of Rituximab to Chemotherapy for Pediatric High-Risk, Mature B-Cell NHL

Lauren Dembeck, PhD

June 26, 2020

For pediatric high-risk B-cell NHL, adding rituximab to standard LMB chemotherapy prolongs event-free and overall survival but may increase adverse events.

Next post in Lymphoma